Singapore, May 31, 2022 – In response to the new Omicron variant (also known as B.1.1.529), we, Credo Diagnostics Biomedical Pte Ltd, have performed the BLASTn analysis (with the oligonucleotide primers and probes of the assays involving SARS-CoV-2 detection) against the sequences listed in GISAID on May 25th, 2022.
According to our analysis, we confirm that our SARS-CoV-2 RNA detection assay* can correctly detect the new Omicron strain, including B.1.1.529 BA.1, BA.2, BA.4, and BA.5.
Meanwhile. we continue to affirm that our SARS-CoV-2 RNA detection assay is still capable of detecting the following earlier variant strains correctly
Another circulating Variant of Concern (VOC):
． Delta variant: known as B.1.617.2
Previously circulating Variants of Concern (VOC):
． Alpha variant: known as B.1.1.7
． Beta variant: known as B.1.351
． Gamma variant: known as P.1
Previously circulating Variants of Interest (VOI)
． Lambda variant: known as C.37
． Mu variant: known as B.1.621
． Eta variant: known as B.1.525
． Iota variant: known as B.1.526
． Kappa variant: known as B.1.617.1
． Zeta variant: known as P.2
． Epsilon variant: known as B.1.427/B.1.429
． Indian variant: known as B.1.617.3
* The SARS-CoV-2 RNA detection assays include:
VitaPCR™ Influenza/SARS-CoV-2 (Flu/SC2) Assay (PCRAE0128)
VitaPCR™ SARS-CoV-2 Gen2 Assay (PCRAE0120)
VitaPCR™ SARS-CoV-2 Assay (PCRAE0114)
About Credo Diagnostics Biomedical Pte. Ltd.
Credo Diagnostics develops and manufactures innovative, easy-to-use and rapid molecular diagnostic solutions for Point-of-Care (POC) applications at affordable costs without compromising accuracy and speed in the areas Human Health. Leveraging solid and established science, combined with efficient integration and strategic innovation, Credo Diagnostics Biomedical provides advanced medical technologies for all.